CYP19A1 and breast carcinoma: 5. Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, et al. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist. 2020;25:e1346-e54.